Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$336 Mln
Revenue (TTM)
$77 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.1 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.5
Industry P/E
--
EV/EBITDA
-0.3
Div. Yield
0 %
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
71,668,702
CFO
$-240.02 Mln
EBITDA
$-283.65 Mln
Net Profit
$-313.24 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sophia Genetics SA (SOPH)
| 8.1 | 12.2 | 8.1 | 59.3 | 0.5 | -- | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
|---|---|---|---|
|
Sophia Genetics SA (SOPH)
| 52.1 | 128.6 | -85.4 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic... modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. The company was incorporated in 2011 and is based in Rolle, Switzerland. Address: La PiEce 12, Rolle, Switzerland, 1180 Read more
Co-Founder, CEO & Director
Dr. Jurgi Camblong M.B.A., Ph.D.
Co-Founder, CEO & Director
Dr. Jurgi Camblong M.B.A., Ph.D.
Headquarters
Rolle
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Sophia Genetics SA (SOPH) is $5.05 (NASDAQ) as of 02-Apr-2026 11:23 EDT. Sophia Genetics SA (SOPH) has given a return of 0.53% in the last 3 years.
Since, TTM earnings of Sophia Genetics SA (SOPH) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-4.02
|
6.74
|
|
2024
|
-3.24
|
2.10
|
|
2023
|
-3.88
|
2.02
|
|
2022
|
-1.51
|
0.66
|
|
2021
|
-10.53
|
2.82
|
The 52-week high and low of Sophia Genetics SA (SOPH) are Rs 5.70 and Rs 2.58 as of 02-Apr-2026.
Sophia Genetics SA (SOPH) has a market capitalisation of $ 336 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Sophia Genetics SA (SOPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.04
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.